A Cancer Drug Under a Cloud

Several troubling but inconclusive studies suggest that EPO, a huge earner for Amgen and J&J, might actually lower survival rates

By Amy Tsao

To continue reading this article you must be a Bloomberg Professional Service Subscriber.